TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16359401

Group type: EXPERIMENTAL
Intervention: Vi polysaccharide (PS) vaccine
Number of subjects: 200000

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200000
Study: 11953977

Group type: EXPERIMENTAL
Intervention: Pulse cyclophosphamide, pulse methylprednisolone, or the combination of both
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Additional immunosuppressive therapy
Number of subjects: 145

Group type: COMPARATOR
Intervention: Complete response
Number of subjects: 145

Group type: COMPARATOR
Intervention: Partial response
Number of subjects: 145
Study: 10215731

Group type: EXPERIMENTAL
Intervention: Ranitidine 25 mg
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Ranitidine 125 mg
Number of subjects: 577

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577
Study: 7824101

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: L/R HF ratios
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MRI volumetric studies
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: HF volume ratios and T2 MRI
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: hippocampal volume and cerebral metabolic rate of glucose asymmetry index
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PET
Number of subjects: 18
Study: 2089142

Group type: EXPERIMENTAL
Intervention: Ubidecarenone (CoQ10)
Number of subjects: 44
Study: 507480

Group type: EXPERIMENTAL
Intervention: Terbutaline 25 ug/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Terbutaline 50 ug/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Terbutaline 100 ug/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Terbutaline 50 ug/kg tid
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Terbutaline 75 or 100 ug/kg tid
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31741317

Group type: EXPERIMENTAL
Intervention: Distractors sharing target color context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distractors sharing target orientation context
Number of subjects: 0
Study: 30893220

Group type: EXPERIMENTAL
Intervention: CNB
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: ANB
Number of subjects: 110

Group type: COMPARATOR
Intervention: FHB
Number of subjects: 110
Study: 27492336

Group type: EXPERIMENTAL
Intervention: 3-day voice rest
Number of subjects: 31

Group type: COMPARATOR
Intervention: 7-day voice rest
Number of subjects: 31
Study: 24368514

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 22804353

Group type: EXPERIMENTAL
Intervention: Preventive blood transfusion
Number of subjects: 237

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 237
Study: 23845131

Group type: EXPERIMENTAL
Intervention: Quality Improvement Initiative (QI)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 6000
Study: 19621834

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy with exposure and response prevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Augmentation of SSRI with atypical antipsychotic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discontinuation of treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring for comorbid depression and suicidal ideation
Number of subjects: 0
Study: 17214404

Group type: EXPERIMENTAL
Intervention: Random whole-body vibration (5 series of 60 seconds each)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (rest period)
Number of subjects: 28
Study: 12634293

Group type: EXPERIMENTAL
Intervention: exercise + HRT (n = 20)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: exercise (n = 24)
Number of subjects: 94

Group type: COMPARATOR
Intervention: HRT (n = 22)
Number of subjects: 94

Group type: COMPARATOR
Intervention: control (n = 28)
Number of subjects: 94
Study: 10634401

Group type: EXPERIMENTAL
Intervention: Protein intake
Number of subjects: 1552

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1552

Group type: EXPERIMENTAL
Intervention: Fiber intake
Number of subjects: 1552

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 1552

Group type: COMPARATOR
Intervention: Calories, fat (animal or vegetable), and carbohydrate intake
Number of subjects: 1552
Study: 9375433

Group type: EXPERIMENTAL
Intervention: Intercessory prayer
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonintervention (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Participants who reported a family member or friend praying for them
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Greater frequency of prayer by participants themselves
Number of subjects: 40
Study: 1548391

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.6 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison boys (without ADHD)
Number of subjects: 32
Study: 3981411

Group type: EXPERIMENTAL
Intervention: Repeat-action combination tablet containing 6 mg of dexbrompheniramine maleate with 120 mg of pseudoephedrine sulfate every 12 h for 7 d
Number of subjects: 12

Group type: COMPARATOR
Intervention: Concomitant administration of conventional 2-mg dexbrompheniramine maleate tablets every 4 h and 120-mg pseudoephedrine sulfate repeat-action tablets every 12 h, each for 7 d
Number of subjects: 12
Study: 30501447

Group type: EXPERIMENTAL
Intervention: Active condition (more than 15,000 steps per day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sedentary condition (less than 1,000 steps per day)
Number of subjects: 16
Study: 30587944

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy (LH)
Number of subjects: 116
Study: 27589059

Group type: EXPERIMENTAL
Intervention: MD1003 (100 mg biotin)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 24583567

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day
Number of subjects: 427

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study: 22348492

Group type: EXPERIMENTAL
Intervention: 5mg/kg oral erythromycin every 6 hours for 14 days (n=19)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (n=26)
Number of subjects: 45
Study: 19136327

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention to reduce severity of oral mucositis and oral pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 17964463

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 15
Study: 15007512

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) + Creatine
Number of subjects: 140
Study: 12363116

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy plus paroxetine (40 mg/day)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Cognitive‐behavioral therapy plus placebo
Number of subjects: 161
Study: 9672949

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Baseline smoking prevalence
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Follow-up smoking cessation rates
Number of subjects: 90
Study: 7721239

Group type: EXPERIMENTAL
Intervention: Granular (G) type duodenitis
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Multi‐polypoid (MP) type duodenitis
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Reddened (R) type duodenitis
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Erosive (E) type duodenitis
Number of subjects: 117

Group type: COMPARATOR
Intervention: Histological analysis of duodenitis specimens
Number of subjects: 117
Study: 2481775

Group type: EXPERIMENTAL
Intervention: Felodipine-ER 10 mg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Felodipine-ER 20 mg
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 1234484

Group type: EXPERIMENTAL
Intervention: Trazodone (single oral dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31727391

Group type: EXPERIMENTAL
Intervention: Nurse-led multidisciplinary self-management program (NMSP)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 144
Study: 31094122

Group type: EXPERIMENTAL
Intervention: 5% Permethrin
Number of subjects: 160

Group type: COMPARATOR
Intervention: 10% Crotamiton
Number of subjects: 160
Study: 27177182

Group type: EXPERIMENTAL
Intervention: Surgical rehearsal platform (SRP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no SRP)
Number of subjects: 25
Study: 26683695

Group type: EXPERIMENTAL
Intervention: HOLA intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fotonovela (control)
Number of subjects: 60
Study: 23193217

Group type: EXPERIMENTAL
Intervention: Closed-loop basal insulin delivery
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional pump therapy
Number of subjects: 12
Study: 21632228

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.4 mg
Number of subjects: 81

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 81
Study: 17566124

Group type: EXPERIMENTAL
Intervention: Levetiracetam (maximum dose 30 mg/kg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15022802

Group type: EXPERIMENTAL
Intervention: Closed suction drainage (CSD)
Number of subjects: 104

Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 104
Study: 12116023

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Famciclovir 500 mg three times a day
Number of subjects: 100
Study: 9537221

Group type: EXPERIMENTAL
Intervention: 75 mg azimilide orally each day
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 100 mg azimilide orally each day
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 7711992

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (HbA1c < 7%)
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional glycemic control (HbA1c > 9%)
Number of subjects: 1441
Study: 2675895

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA; 2 mg/kg per day) in combination with CyA (group AZA+)
Number of subjects: 78

Group type: COMPARATOR
Intervention: CyA alone (group AZA‐)
Number of subjects: 78
Study: 593193

Group type: EXPERIMENTAL
Intervention: Triphasic preparation with a sequence of 6/5/10
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Triphasic preparation with a reduced content of total dose of oestrogen per cycle
Number of subjects: 10
Study: 31062517

Group type: EXPERIMENTAL
Intervention: Immediate functional loading (screw‐retained or cemented single or splinted restorations in full occlusal contact)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Immediate nonfunctional loading (screw‐retained or cemented single or splinted restorations in infraocclusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Patient satisfaction assessment using a questionnaire with visual analog scales
Number of subjects: 20
Study: 28444950

Group type: EXPERIMENTAL
Intervention: Prone position for 5 hours without PFCO
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Supine position for 5 hours without PFCO
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Prone position for 5 hours with PFCO
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Supine position for 5 hours with PFCO
Number of subjects: 56
Study: 25870057

Group type: EXPERIMENTAL
Intervention: BMS‐663068 at 600 mg BID
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: BMS‐663068 at 600 mg BID plus RTV at 100 mg QD
Number of subjects: 36

Group type: COMPARATOR
Intervention: ATV/r (ATV at 300 mg QD plus RTV at 100 mg QD)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: BMS‐663068 at 600 mg BID plus ATV at 300 mg QD plus RTV at 100 mg QD
Number of subjects: 36
Study: 24579286

Group type: EXPERIMENTAL
Intervention: Chewing gum containing tea polyphenol
Number of subjects: 157

Group type: COMPARATOR
Intervention: Chewing gum without tea polyphenol (control gum)
Number of subjects: 157

Group type: COMPARATOR
Intervention: No chewing gum (no gum group)
Number of subjects: 157
Study: 21477057

Group type: EXPERIMENTAL
Intervention: Alcohol commercials
Number of subjects: 184

Group type: COMPARATOR
Intervention: Nonalcohol commercials
Number of subjects: 184
Study: 19061743

Group type: EXPERIMENTAL
Intervention: Addition of 10% of body mass in weight belt
Number of subjects: 84

Group type: COMPARATOR
Intervention: No weight belt (control)
Number of subjects: 84
Study: 15858159

Group type: EXPERIMENTAL
Intervention: 20 Hz (16-24 Hz) activity suppression during mouth movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task-related change in 20 Hz activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-speech movements
Number of subjects: 0
Study: 15635512

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Patient-controlled interscalene analgesia with 0.15% bupivacaine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Patient-controlled interscalene analgesia with 0.15% ropivacaine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Both groups (bupivacaine and ropivacaine)
Number of subjects: 44
Study: 12056469

Group type: EXPERIMENTAL
Intervention: Tissucol
Number of subjects: 56
Study: 10179922

Group type: EXPERIMENTAL
Intervention: Diclofenac/misoprostol (Arthrotec®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NSAID therapy (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gastroprotective NSAIDs
Number of subjects: 0
Study: 7917153

Group type: EXPERIMENTAL
Intervention: Human Ser-Tyr28 ANH (0.6 pmol/kg/min) infusion during low-salt diet (LS+ANH)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo infusion during low-salt diet (LS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo infusion during high-salt diet (HS)
Number of subjects: 8
Study: 2576363

Group type: EXPERIMENTAL
Intervention: picumast dihydrochloride 1 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 99
Study: 765435

Group type: EXPERIMENTAL
Intervention: Cloward procedure (anterior approach)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Radical discectomy and foraminotomy
Number of subjects: 51
Study: 31789554

Group type: EXPERIMENTAL
Intervention: Alcoholic beverage (target BrAC = .08 g%)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 145
Study: 30496426

Group type: EXPERIMENTAL
Intervention: Good value estimation methodology (total cholesterol of 170 mg/dl and HDL‐cholesterol of 50 mg/dl)
Number of subjects: 345440

Group type: EXPERIMENTAL
Intervention: Formal imputation methodology
Number of subjects: 345440
Study: 27013221

Group type: EXPERIMENTAL
Intervention: Acceptance Commitment Therapy (ACT) intervention; 6 sessions
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 31
Study: 26606003

Group type: EXPERIMENTAL
Intervention: High-volume injectate (8 mL)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Low-volume injectate (3 mL)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study: 23368828

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg of body mass/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 30
Study: 22364063

Group type: EXPERIMENTAL
Intervention: School-based intervention program
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study: 19889067

Group type: EXPERIMENTAL
Intervention: EAC (esomeprazole 20 mg b.d., amoxycillin 1 g b.d., and clarithromycin 500 mg b.d.)
Number of subjects: 300

Group type: COMPARATOR
Intervention: EAL (esomeprazole 20 mg b.d., amoxycillin 1 g b.d., and levofloxacin 500 mg daily)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: EAC
Number of subjects: 300

Group type: COMPARATOR
Intervention: EAL
Number of subjects: 300
Study: 17230483

Group type: EXPERIMENTAL
Intervention: Unilateral deep brain stimulation of the subthalamic nucleus (STN)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Unilateral deep brain stimulation of the globus pallidus internus (GPi)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Unilateral deep brain stimulation of either STN or GPi
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Preoperative medication responsiveness
Number of subjects: 33
Study: 14764786

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment with dosages of 1 mg/m².d and 2 mg/m².d (approximately 0.035 and 0.070 mg/kg.d, respectively) for 1 year
Number of subjects: 351

Group type: COMPARATOR
Intervention: Control group (normal-statured children born appropriate for gestational age)
Number of subjects: 351
Study: 11905723

Group type: EXPERIMENTAL
Intervention: Meta-analysis of randomised clinical trials in oncology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta-analysis using individual patient data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta-analysis of individual patient data
Number of subjects: 0
Study: 8997462

Group type: EXPERIMENTAL
Intervention: Topical antimicrobial gels containing 4 times minimally inhibitory in vitro concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical antimicrobial gels containing 8 times minimally inhibitory in vitro concentrations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study: 8203854

Group type: EXPERIMENTAL
Intervention: Aztreonam (6 g/day [2 g intravenously every 8 h] for 10 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Chloramphenicol (50 mg/kg of body weight per day [intravenously or orally] for 14 days)
Number of subjects: 44
Study: 3555596

Group type: EXPERIMENTAL
Intervention: PUVA with oral 8‐methoxypsoralen (8‐MOP)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: UVB with oral placebo
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control low‐dose UVA with oral placebo
Number of subjects: 42
Study: 30865022

Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound treatment
Number of subjects: 57

Group type: COMPARATOR
Intervention: Baseline stiffness
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Improvement in stiffness
Number of subjects: 57
Study: 27903827

Group type: EXPERIMENTAL
Intervention: Auricular acupressure applied to seven auricular acupoints for 6 weeks using vaccaria seeds
Number of subjects: 52
Study: 27084116

Group type: EXPERIMENTAL
Intervention: SASA! community mobilisation intervention
Number of subjects: 1583
Study: 24562804

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 2995

Group type: COMPARATOR
Intervention: Control (no tirofiban)
Number of subjects: 2995
Study: 22309432

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sodium bicarbonate infusion (control)
Number of subjects: 72
Study: 20643194

Group type: EXPERIMENTAL
Intervention: Nicotine gum (6 mg)
Number of subjects: 24
Study: 17549324

Group type: EXPERIMENTAL
Intervention: ICF Brief Core Set
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: ICF Comprehensive Core Set
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Inter-rater agreement
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Addition of codes d920 and d650
Number of subjects: 402
Study: 16172545

Group type: EXPERIMENTAL
Intervention: Desipramine (50 mg once daily)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg once daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 12163662

Group type: EXPERIMENTAL
Intervention: Soybean isoflavone glycosides
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Red clover isoflavone aglycones
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (washout period)
Number of subjects: 14
Study: 9790130

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 192

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 192
Study: 9097762

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 39
Study: 2692764

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moclobemide
Number of subjects: 0
Study: 345632

Group type: EXPERIMENTAL
Intervention: Meglumine iodamide (0.8 cc/kg to a maximum of 55 cc)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Renografin 60 (52% meglumine diatrizoate and 8% sodium diatrizoate) (0.8 cc/kg to a maximum of 55 cc)
Number of subjects: 50
Study: 31538976

Group type: EXPERIMENTAL
Intervention: Guided imagery audio file for 20 minutes per day for one week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29282115

Group type: EXPERIMENTAL
Intervention: Modified transvaginal mesh surgery (mTVM group, n = 65)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Original transvaginal mesh surgery (TVM group, n = 65)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both groups (mTVM and TVM)
Number of subjects: 130
Study: 25722067

Group type: EXPERIMENTAL
Intervention: LEDT at 210 J (40 s)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LEDT at 315 J (60 s)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0 J)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LEDT at 105 J (20 s)
Number of subjects: 12
Study: 24322420

Group type: EXPERIMENTAL
Intervention: 20 mg of ATP injected before PVI in AF patients
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 20 mg of ATP injected in AVRT patients
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: ATP-induced AF
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Spontaneous AF
Number of subjects: 125
Study: 21960668

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg single dose)
Number of subjects: 20
Study: 19678944

Group type: EXPERIMENTAL
Intervention: TTT intervention (Train the trainer)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 168